News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acura Pharmaceuticals, Inc. Announces Investigational New Drug Application


3/16/2010 8:55:54 AM

PALATINE, Ill., March 15, 2010 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced clinical evaluation is now allowed under an Investigational New Drug application ("IND") filed with the U.S. Food and Drug Administration ("FDA") for a benzodiazepine product candidate utilizing our Aversion® Technology. The primary active ingredient in this product candidate is intended for the treatment of anxiety disorders. Aversion® Technology is a unique mixture of active and functional inactive ingredients, intended to minimize abuse liability potential of the primary active ingredient. Benzodiazepine products are classified as Schedule IV for potential abuse by the U.S. Drug Enforcement Administration ("DEA"). Acura has now opened three INDs for Aversion® Technology product candidates.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES